Analyst consensus rating
LENZ Therapeutics Analyst Rating: none
LENZ is rated none by 7 analysts with a $24.00 target. As of 2026-08-28.
Direct answer
LENZ Therapeutics's consensus rating is none.
7 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $24.00.
Forecast evidence checked August 28, 2026.
Get free LENZ Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $4.81
- Average price target
- $24.00
- High price target
- $60.00
- Low price target
- $7.00
- Low target gap
- +45.5%
- Target upside
- +399%
- High target gap
- +1,147.4%
- Target range width
- 1,101.9%
- Consensus rating
- none
- Analysts
- 7
- Evidence date
- August 28, 2026
- Valid through
- September 4, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for LENZ Therapeutics?
LENZ Therapeutics has a verified none consensus. The same dataset has an average price target of $24.00.
How far are LENZ Therapeutics's low and high targets from the recorded price?
The low target implies +45.5%, while the high target implies +1,147.4%.
How many analysts are included in LENZ Therapeutics's consensus?
The verified consensus includes 7 analysts.
How is LENZ Therapeutics's target upside or downside calculated?
The average target of $24.00 is divided by the recorded price of $4.81, then one is subtracted to produce +399%. This does not guarantee a future return.
When was LENZ Therapeutics's analyst forecast verified?
The data was verified on 2026-08-28. The dataset is valid through 2026-09-04.